These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30841862)

  • 1. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
    Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
    BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
    Dong GY; Meng YH; Xiao XJ
    Medicine (Baltimore); 2022 Sep; 101(36):e30347. PubMed ID: 36086713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
    J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of rituximab in refractory neuromyelitis optica.
    Collongues N; Brassat D; Maillart E; Labauge P; Ouallet JC; Carra-Dalliere C; Moreau T; Bourre B; Papeix C; Brochet B; Audoin B; Vukusic S; de Seze J; Marignier R;
    Mult Scler; 2016 Jun; 22(7):955-9. PubMed ID: 26362900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
    J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
    Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
    Damato V; Evoli A; Iorio R
    JAMA Neurol; 2016 Nov; 73(11):1342-1348. PubMed ID: 27668357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder.
    Thakolwiboon S; Zhao-Fleming H; Karukote A; Mao-Draayer Y; Flanagan EP; Avila M
    Mult Scler Relat Disord; 2021 Nov; 56():103310. PubMed ID: 34634625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
    J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.